Redonyl Ultra coming to North America in May
The nutraceutical is promoted as part of a multimodal approach to canine atopic dermatitis.
North American veterinarians in May will gain access to Redonyl Ultra, a nutraceutical formulated to support skin function and the treatment of atopic dermatitis in dogs.
Dechra Veterinary Products will distribute Redonyl Ultra under an agreement signed with Premune, a Swedish-based animal health company.
The companies noted that Redonyl Ultra contains palmitoylethanolamide (PEA), a naturally occurring biomodulator that is ultra-micronized in the product for “improved distribution and diffusion” in the body.
“Due to the patents held on Redonyl Ultra, no other animal health nutraceutical can contain micronized or ultra-micronized PEA,” they reported.
Dechra’s European division launched Redonyl Ultra overseas in May 2017.
“I strongly believe Dechra North America has what it takes to replicate the success that Redonyl Ultra and PEA [have] seen in Europe,” said Premune CEO Viktor Karlsson.
Redonyl Ultra is positioned as part of a multimodal solution for veterinarians treating cases of atopic dermatitis. The nutraceutical comes in soft-chew strengths of 100 and 200 milligrams.
Dechra Veterinary Products is headquartered in Overland Park, Kansas.